CAMBRIDGE, MA, USA, May 9, 2024 – Cambridge-based Advise Connect Inspire, LLC (ACI) is thrilled to announce its role in supporting the Therapeutics and Vaccines hub of the BARDA Accelerator Network (BAN), in partnership with Start2 and BioLabs. The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, leverages public-private partnerships to develop vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).
The BARDA Accelerator Network’s Vaccine Innovation and Therapeutics Acceleration Launchpad (VITAL) will accelerate the development of next-generation therapeutic and vaccine platforms and technologies by collaborating with companies globally. (VITAL) is led by Start2 with ACI and Biolabs as strategic partners. ACI, leveraging its expertise from the successful GoldTrack program, supported 45 companies from Europe, Canada, and the US, in raising over $500 million. This experience positions ACI to provide crucial support to companies worldwide.
“The opportunity to support BARDA’s Therapeutics and Vaccines Hub is a testament to ACI’s commitment to driving innovation and enhancing national health security,” stated Steven Laken, CEO at ACI. “We are proud to leverage our expertise acquired through the GoldTrack program to support companies in their quest to develop and deploy critical healthcare solutions.” This announcement comes not too long after one of the GoldTrack companies, OchreBio signed a $1.3B deal with Boehringer Ingelheim to treat metabolic-associated steatohepatitis (MASH), through RNA therapies.
The BARDA Accelerator Network will launch four additional hubs to establish a robust health security innovation ecosystem. Wraparound accelerator support services and funding for rapid development, evaluation, and validation will support the commercialization of health security technologies and products.
Media Contact:
Raquel Riera
Sr. Program Director
Raquel@aci-lifesciences.com
